Please assess the completion status of the following clinical trial:

Trial Title: Mini-CHOP and Rituximab in Patients Aged Over 80 Years

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification). DLBCL with some small cell infiltration in bone marrow or lymph node may be included.~* Aged over 80 years.~* Ann Arbor stage I bulky, II, III or IV~* Age-adjusted International Prognostic Index equal to 0, 1, 2 and 3.~* Patient non previously treated.~* ECOG performance status ≤ 2.~* With a minimum life expectancy of 3 months.~* Negative HIV, HBV and HCV serologies test ≤ 4 weeks (except after vaccination).~* Having previously signed a written informed consent~Exclusion Criteria:~* Any other histological type of lymphoma.~* Any history of treated or non-treated indolent lymphoma.~* Central nervous system or meningeal involvement by lymphoma.~* Contra-indication to any drug contained in the chemotherapy regimens.~* Any serious active disease (according to the investigator's decision).~* Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~* Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration.~* Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~* Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~* Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R mini CHOP (Type: EXPERIMENTAL): Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).